

Federal Communications Commission.

**Gary Michaels,**

*Chief, Legal Branch, Auctions and Industry Analysis Division.*

[FR Doc. 03-29449 Filed 11-24-03; 8:45 am]

BILLING CODE 6712-01-P

Commission's November 17, 2003 Order.

**Bryant L. VanBrakle,**  
*Secretary.*

[FR Doc. 03-29415 Filed 11-24-03; 8:45 am]

BILLING CODE 6730-01-P

## Correction

In the **Federal Register** of November 10, 2003, in FR Doc. 03-28197, on page 63799 in the first column at letter "B" replace the first sentence to read: "Hypertension 2000 paper #2: Figure 1A merited retraction."

Dated: November 18, 2003.

**Lawrence J. Rhoades,**

*Acting Director, Office of Research Integrity.*

[FR Doc. 03-29335 Filed 11-24-03; 8:45 am]

BILLING CODE 4150-31-P

## FEDERAL MARITIME COMMISSION

[Docket No. 03-14]

### Revocation of Licenses and Order To Discontinue Operations in U.S.— Foreign Trades for Failure To Comply With the Requirements of the Ocean Shipping Reform Act of 1998; Notice of Show Cause Proceeding

November 20, 2003.

Notice is given that, on November 17, 2003, the Federal Maritime Commission ("Commission") served an Order to Show Cause ("Order") on fourteen (14) non-vessel-operating common carrier ("NVOCC")/ocean transportation intermediaries ("OTIs").

Commission regulations require that each NVOCC in the United States must be licensed and, among other requirements, file a Form FMC-1 indicating the location of its electronically published tariff. The 14 NVOCCs listed in the Commission's Order each maintain an OTI license issued by the Commission, but have otherwise failed to establish or maintain an electronically published tariff and to maintain a current Form FMC-1 on file with the Commission. The Commission now proposes to revoke the licenses of these NVOCCs for said failures, and to direct them to cease and desist from operating in the U.S.-foreign trades.

The Order directs the 14 NVOCCs to show cause why the Commission should not revoke their respective licenses for failure to comply with sections 8 and 19 of the Shipping Act of 1984, 46 U.S.C. app. § 1707 and § 1718, as amended, and 46 CFR part 515.

The Order's full text may be viewed on the Commission's Home page at <http://www.fmc.gov>, or at the Office of the Secretary, Room 1046, 800 N. Capitol Street, NW., Washington, DC. Any person having an interest and desiring to intervene in this proceeding shall file a petition for leave to intervene in accordance with Rule 72 of the Commission's Rules of Practice and Procedure, 46 CFR 502.72, and the procedural schedule set forth in the

## GENERAL SERVICES ADMINISTRATION

### Office of Governmentwide Policy; Revision of a Standard Form by the Department of the Treasury

AGENCY: Office of Governmentwide Policy, GSA.

ACTION: Notice.

**SUMMARY:** The Department of the Treasury revised SF 3881, ACH Vendor/Miscellaneous Payment Enrollment to:

Remove the CTP checkbox and the OMB expiration; and

Authorize form for local reproduction. This was due to low demand in the Federal Supply Service.

You can obtain the updated form in two ways:

On the internet. Address: <http://w3.gsa.gov/web/c/newform.nsf/MainMenu?OpenForm> or;

From GSA, Forms-MCF, Attn.: Barbara Williams, (202) 501-0581.

**FOR FURTHER INFORMATION CONTACT:** Ms. Lois Holland (202) 622-1563. This contact is for information about completing the form only.

**DATES:** Effective November 25, 2003.

Dated: November 18, 2003.

**Barbara M. Williams,**

*Deputy Standard and Optional Forms Management Officer, General Services Administration.*

[FR Doc. 03-29362 Filed 11-24-03; 8:45 am]

BILLING CODE 6820-34-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Office of the Secretary

#### Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice; correction.

**SUMMARY:** The Office of the Secretary, HHS, published a notice in the **Federal Register** of November 10, 2003, concerning a finding of scientific misconduct regarding Dr. Gelband. The document contained a typographical error.

**FOR FURTHER INFORMATION CONTACT:** Director, Division of Investigative Oversight, Office of Research Integrity, 301-443-5330.

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket Nos. 2002E-0099, 2002E-0184, and 2003E-0255]

#### Determination of Regulatory Review Period for Purposes of Patent Extension; XIGRIS

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

**SUMMARY:** The Food and Drug Administration (FDA) has determined the regulatory review period for XIGRIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of three applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of three patents which claim that human biological product.

**ADDRESSES:** Submit written comments and petitions to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to <http://www.fda.gov/dockets/ecomments>.

**FOR FURTHER INFORMATION CONTACT:** Claudia V. Grillo, Office of Regulatory Policy (HFD-013), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 240-453-6699.

**SUPPLEMENTARY INFORMATION:** The Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417) and the Generic Animal Drug and Patent Term Restoration Act (Public Law 100-670) generally provide that a patent may be extended for a period of up to 5 years so long as the patented item (human drug product, animal drug product, medical device, food additive, or color additive) was subject to regulatory review by FDA before the item was marketed. Under these acts, a product's regulatory review period forms the basis for determining the